MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 598914 | Name: Lincosamine

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Lincosamine is a lincosamide antibiotic produced by Streptomyces lincolnensis.

Chemical Structure

Lincosamine
Lincosamine
CAS#13006-69-4

Theoretical Analysis

MedKoo Cat#: 598914

Name: Lincosamine

CAS#: 13006-69-4

Chemical Formula: C8H17NO6

Exact Mass: 223.1056

Molecular Weight: 223.22

Elemental Analysis: C, 43.05; H, 7.68; N, 6.27; O, 43.00

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
Lincosamine;
IUPAC/Chemical Name
(3R,4S,5R,6R)-6-((1R,2R)-1-amino-2-hydroxypropyl)tetrahydro-2H-pyran-2,3,4,5-tetraol
InChi Key
KOFBVFFPLADGGO-DUSUDKPKSA-N
InChi Code
InChI=1S/C8H17NO6/c1-2(10)3(9)7-5(12)4(11)6(13)8(14)15-7/h2-8,10-14H,9H2,1H3/t2-,3-,4+,5-,6-,7-,8?/m1/s1
SMILES Code
C[C@@H](O)[C@@H](N)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)C(O)O1
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.03.00
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 223.22 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Johnson DM, Erwin ME, Barrett MS, Gooding BB, Jones RN. Antimicrobial activity of ten macrolide, lincosamine and streptogramin drugs tested against Legionella species. Eur J Clin Microbiol Infect Dis. 1992 Aug;11(8):751-5. PubMed PMID: 1425738. 2: Marshall JA, Beaudoin S. Stereoselective Synthesis of Differentially Protected Derivatives of the Higher Amino Sugars Destomic Acid and Lincosamine from Serine and Threonine. J Org Chem. 1996 Jan 26;61(2):581-586. PubMed PMID: 11666978. 3: Gemmell CG. [Lincosamine as indirect biological response modifier]. Z Arztl Fortbild (Jena). 1992 Mar 25;86(6):277-9. Review. German. PubMed PMID: 1590006. 4: van Delft FL, de Kort M, van Der Marel GA, van Boom JH. Use of a Novel alpha-Hydroxyethylating Reagent in the Stereoselective Synthesis of Lincosamine. J Org Chem. 1996 Mar 8;61(5):1883-1885. PubMed PMID: 11667071. 5: Brown J, Freeman BB 3rd. Combining quinupristin/dalfopristin with other agents for resistant infections. Ann Pharmacother. 2004 Apr;38(4):677-85. Epub 2004 Feb 27. Review. PubMed PMID: 14990776. 6: Argoudelis AD, Brodasky TF. Letter: Studies with Streptomyces caelestis. III. New antibiotics containing lincosamine or celestosamine. J Antibiot (Tokyo). 1974 Aug;27(8):642-5. PubMed PMID: 4436149. 7: O'Dowd H, Lewis JG, Trias J, Asano R, Blais J, Lopez SL, Park CK, Wu C, Wang W, Gordeev MF. Novel antibacterial azetidine lincosamides. Bioorg Med Chem Lett. 2008 Apr 15;18(8):2645-8. doi: 10.1016/j.bmcl.2008.03.032. Epub 2008 Mar 14. PubMed PMID: 18359228. 8: Belov BS. [Pharyngeal A-streptococcal infection encountered in the practical work of an internal medicine specialist]. Vestn Otorinolaringol. 2013;(3):39-43. Review. Russian. PubMed PMID: 23887373. 9: Mohammadi S, Sekawi Z, Monjezi A, Maleki MH, Soroush S, Sadeghifard N, Pakzad I, Azizi-Jalilian F, Emaneini M, Asadollahi K, Pourahmad F, Zarrilli R, Taherikalani M. Emergence of SCCmec type III with variable antimicrobial resistance profiles and spa types among methicillin-resistant Staphylococcus aureus isolated from healthcare- and community-acquired infections in the west of Iran. Int J Infect Dis. 2014 Aug;25:152-8. doi: 10.1016/j.ijid.2014.02.018. Epub 2014 Jun 5. PubMed PMID: 24909489. 10: Dondoni A. Heterocycles in organic synthesis: thiazoles and triazoles as exemplar cases of synthetic auxiliaries. Org Biomol Chem. 2010 Aug 7;8(15):3366-85. doi: 10.1039/c002586k. Epub 2010 May 26. PubMed PMID: 20505853. 11: Shivakumar AG, Dubnau D. Characterization of a plasmid-specified ribosome methylase associated with macrolide resistance. Nucleic Acids Res. 1981 Jun 11;9(11):2549-62. PubMed PMID: 6792593; PubMed Central PMCID: PMC326871. 12: Argudín MA, Tenhagen BA, Fetsch A, Sachsenröder J, Käsbohrer A, Schroeter A, Hammerl JA, Hertwig S, Helmuth R, Bräunig J, Mendoza MC, Appel B, Rodicio MR, Guerra B. Virulence and resistance determinants of German Staphylococcus aureus ST398 isolates from nonhuman sources. Appl Environ Microbiol. 2011 May;77(9):3052-60. doi: 10.1128/AEM.02260-10. Epub 2011 Mar 4. PubMed PMID: 21378035; PubMed Central PMCID: PMC3126402. 13: Stratton CW. Dead bugs don't mutate: susceptibility issues in the emergence of bacterial resistance. Emerg Infect Dis. 2003 Jan;9(1):10-6. Review. PubMed PMID: 12533275; PubMed Central PMCID: PMC2873758. 14: Lewis MT, Jones RN. Activity of macrolides, lincosamines, streptogramins and fluoroquinolones against streptococcus pneumoniae and enterococci isolates from the western hemisphere: example of international surveillance (SENTRY antimicrobial surveillance program )in the development of new drugs. Braz J Infect Dis. 2000 Feb;4(1):15-21. PubMed PMID: 10788841. 15: Ben Hassen A, Ben Abdallah T, Kamoun A, Fendri C, Benalgia S, Matri A, Ben Redjeb S. [Staphylococcus aureus nosocomial infections in an intensive care milieu (1985-1989) in Tunis]. Bull Soc Pathol Exot. 1992;85(4):271-5. French. PubMed PMID: 1446173.

View History

TMI-105795

TMI-105795